scispace - formally typeset
Proceedings ArticleDOI

Use Of Angiotensin Converting Enzyme Inhibitors Or Angiotensin Receptor Blockers And Clinical Outcomes Among Patients At-risk For Acute Lung Injury

Reads0
Chats0
About
This article is published in American Thoracic Society International Conference.The article was published on 2011-05-01. It has received 6 citations till now. The article focuses on the topics: Angiotensin II receptor type 1 & Angiotensin-converting enzyme.

read more

Citations
More filters
Journal ArticleDOI

Fifty Years of Research in ARDS. Is Acute Respiratory Distress Syndrome a Preventable Disease

TL;DR: In this review, the rationale, current evidence, and future directions in ARDS prevention are summarized.
Journal ArticleDOI

Clinical review: Early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure

TL;DR: Current strategies that target prevention of ALI and some of the most promising pharmacologic agents for early treatment ofALI prior to the onset of respiratory failure that requires mechanical ventilation are discussed.
Journal ArticleDOI

Acute Respiratory Distress Syndrome: Etiology, Pathogenesis, and Summary on Management:

TL;DR: The acute respiratory distress syndrome has multiple causes and is characterized by acute lung inflammation and increased pulmonary vascular permeability, leading to hypoxemic respiratory failure and bilateral pulmonary radiographic opacities.
Journal ArticleDOI

Emerging therapies for the prevention of acute respiratory distress syndrome.

TL;DR: It is postulate that overall morbidity and mortality rates from ARDS in the future will be contingent upon decreasing the overall incidence of ARDS through effective identification of those at risk and early application of proven supportive care and pharmacological interventions.
Journal ArticleDOI

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development

TL;DR: To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Related Papers (5)